EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase II)Open Access · CC BY-NC 4.0

Frontline ATRA ‐ ATO Therapy for Acute Promyelocytic Leukemia in Japan: Results From the Prospective Multicenter FBMTG ‐ APL2017 Trial

Ken Takase, Tomohiko Kamimura, Takuro Kuriyama, Takahito Tokuyama, Hideho Henzan, Yoshikane Kikushige, Ilseung Choi, Yutaka Imamura, Akio Mori, Shuki Ohya, Noriaki Kawano, Koji Yonemoto und 3 weitere

Cancer Science · 2026

DOI: 10.1111/cas.70328 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Science, 2026. Verfasst von Ken Takase und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Clinical Research Institute, NHO Kyushu Medical Center, Fukuoka, Japan. Hauptthemen laut MEDLINE: Leukemia, Promyelocytic, Acute, Arsenic Trioxide, Tretinoin, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: JSPS KAKENHI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

All‐trans retinoic acid (ATRA) combined with arsenic trioxide (ATO) has become the international standard of care for newly diagnosed acute promyelocytic leukemia (APL), demonstrating superior efficacy and safety over ATRA–chemotherapy regimens. However, in Japan, ATO has been approved only for relapsed/refractory APL, and prospective data on its frontline use are lacking. We conducted FBMTG‐APL2017, a prospective multicenter phase II trial in Japan, to evaluate ATRA–ATO in newly diagnosed APL patients, including both low–intermediate‐risk and high‐risk groups. Eighty‐one patients were enrolled between 2017 and 2021 and treated with ATRA plus delayed ATO during induction, followed by four cycles of ATRA–ATO consolidation. Complete remission was achieved in 95.1% of patients. With a median follow‐up of 55 months, 3‐year disease‐free survival (DFS) and overall survival (OS) were 93.6% and 95.0%, respectively, consistent with international ATRA–ATO trials. DFS was 96.9% in low–intermediate‐risk and 80.0% in high‐risk patients, with no significant difference. Molecular remission was achieved in 99% after consolidation, and only two molecular relapses occurred. Differentiation syndrome developed in 56.8% but was generally manageable, with only one fatal case; early death occurred in 4.9%, comparable to international data. These results provide the first prospective evidence in Japan that frontline chemo‐free ATRA–ATO is highly effective and safe across all risk groups. They support its adoption as a new standard therapy and bridge the gap with established global practice. Trial Registration: Japan Registry of Clinical Trials: jRCTs071180040

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Promyelocytic, AcuteArsenic TrioxideTretinoinAntineoplastic Combined Chemotherapy ProtocolsHumansJapanFemaleProspective StudiesAdultMiddle AgedMaleAgedDisease-Free SurvivalYoung AdultRemission InductionAdolescentTreatment Outcome

Stichwörter der Autor:innen

Japanese populationacute promyelocytic leukemiaall‐trans retinoic acidarsenic trioxidemeasurable residual disease

Substanzen

Arsenic TrioxideTretinoin

Autor:innen und Institutionen

  • Department of Hematology and Clinical Research Institute, NHO Kyushu Medical Center, Fukuoka, Japan.
  • Department of Hematology, Harasanshin Hospital, Fukuoka, Japan.
  • Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan.
  • Department of Hematology, Matsuyama Red Cross Hospital, Matsuyama, Japan.
  • Division of Hematology and Oncology, Department of Medicine, Fukuoka Red Cross Hospital, Fukuoka, Japan.
  • Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medicine, Fukuoka, Japan.

ORCID-Profile: Toshihiro Miyamoto

Förderung

  • JSPS KAKENHI

Zitieren

APA

Takase, K., Kamimura, T., Kuriyama, T., Tokuyama, T., Henzan, H., Kikushige, Y., Choi, I., Imamura, Y., Mori, A., Ohya, S., Kawano, N., Yonemoto, K., Harada, M., Akashi, K., & Miyamoto, T. (2026). Frontline ATRA ‐ ATO Therapy for Acute Promyelocytic Leukemia in Japan: Results From the Prospective Multicenter FBMTG ‐ APL2017 Trial. Cancer Science. https://doi.org/10.1111/cas.70328

Vancouver

Takase K, Kamimura T, Kuriyama T, Tokuyama T, Henzan H, Kikushige Y, et al. Frontline ATRA ‐ ATO Therapy for Acute Promyelocytic Leukemia in Japan: Results From the Prospective Multicenter FBMTG ‐ APL2017 Trial. Cancer Science. 2026. doi:10.1111/cas.70328

BibTeX
@article{Takase2026,
  author = {Takase, Ken and Kamimura, Tomohiko and Kuriyama, Takuro and Tokuyama, Takahito and Henzan, Hideho and Kikushige, Yoshikane and Choi, Ilseung and Imamura, Yutaka and Mori, Akio and Ohya, Shuki and Kawano, Noriaki and Yonemoto, Koji and Harada, Mine and Akashi, Koichi and Miyamoto, Toshihiro},
  title = {Frontline ATRA ‐ ATO Therapy for Acute Promyelocytic Leukemia in Japan: Results From the Prospective Multicenter FBMTG ‐ APL2017 Trial},
  journal = {Cancer Science},
  year = {2026},
  doi = {10.1111/cas.70328}
}
Kostenlos starten →